|
|
|
|
|
|
Sunday, 26th March 2017, 17:00 – 19:00
Les Goudes 2, Palais des Congrès – Marseille Chanot
|
|
|
|
|
|
The information
in this email is
intended only for
healthcare
professionals
in
Europe, the
Middle East and
Asia Pacific.
|
|
|
|
ECP Immunomodulation: The importance of avoiding immune dysfunction and inducing tolerance for GvHD patients
|
|
|
|
Co-Chairs: Professor Gerard Socié and Andrea Bacigalupo
|
|
|
|
17.00 – 17.15
|
Welcome and Introduction
Professor Gerard Socié, Paris, France and Professor Andrea Bacigalupo, Rome, Italy
|
|
|
|
17.15 – 17.45
|
Achieving Immunotolerance in GvHD – Mechanisms behind Apoptotic Cell-Based Therapies
Professor Adrián E. Morelli, Pittsburgh, US
|
|
|
|
17.45 – 18.15
|
Immunomodulation via ECP in patients with Skin Involvement – Perspective of a Dermatologist
Professor Jean-David Bouaziz, Paris, France
|
|
|
|
18.15 – 18.45
|
Looking in the Mirror: What lessons can be learned from chronic allograft dysfunction after lung transplantation about chronic pulmonary GvHD?
Dr Mark Greer, Hannover, Germany
|
|
|
|
18.45 – 19.00
|
Extracorporeal Photopheresis as second line treatment of cGvHD – A Health Economic assessment
Dr Carlos Crespo, Barcelona, Spain
|
|
|
|
Therakos will be exhibiting at EBMT 2017. Come along to stand 17 to meet the team.
|
|
|
|
|
|
|
